CLIA
Veridien Climate Action ETF
Set alert
18.61 USD 0.00 0.00%
18.55 Day range 18.61
16.48 52-week range 21.19
- Open
- 18.58
- Prev close
- 18.61
- Mkt cap
- 25.40M
- Vol
- 75.56K
- Avg vol
- 36.44K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 18.55
- High
- 18.61
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 19.37
- 200-d avg
- 19.18
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 19.37
- 200-day average
- 19.18
About Veridien Climate Action ETF
The fund seeks to achieve its investment objective by investing in equity securities (or corresponding American Depositary Receipts (“ADRs”)) of U.S. and foreign companies, whose activities, business models, or products make a substantial contribution to mitigating climate change. The fund invests in ADRs to gain exposure to foreign companies, which may include those based in both developed and emerging markets.
News
- Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue
- ESMO 2026 Presentations Deepen the Evidence Base for Natera's Oncology Portfolio and Leadership in Ultrasensitive MRD Technology
- Natera's Signatera™ MRD Test Named to TIME's List of the Best Inventions of 2026
- bioAffinity Technologies to Present New Perspectives on CyPath® Lung's Use for Cancer Risk Assessment at CHEST 2026
- Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
- bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026
- DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division
- bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
- bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm
- New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
Your note
Sign in to keep a note on CLIA — it syncs with the Stock Master app.